Pharmacological profile of KE-758, the main metabolite of the antirheumatic agent KE-298.
KE-298(2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid) is a newly developed antirheumatic drug which suppresses the development of arthritis in animal models and has immunomodulatory effects. KE-298 is converted into the deacetylated form, KE-758 (2-mercaptomethyl-4-(4-methylphenyl)-4-oxobutanoic acid), the main serum metabolite in humans, and circulates in peripheral blood following oral administration. The authors compared effects of KE-758 and KE-298 on inflammatory cytokine production from human peripheral blood mononuclear cells and human umbilical vein endothelial cells (HUVEC), interleukin-1 (IL-1)-induced thymocyte proliferation (LAF) activity, adjuvant-induced arthritis in rats and lymphocyte transformation test in mice. KE-758 exhibited almost the same effect as KE-298 both in vitro and in vivo. The authors consider that KE-758 is pharmacologically a metabolite form of KE-298, in vivo.